Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Operating Income (2016 - 2025)

Perspective Therapeutics' Operating Income history spans 15 years, with the latest figure at -$45.0 million for Q4 2024.

  • For Q4 2024, Operating Income fell 285.27% year-over-year to -$45.0 million; the TTM value through Dec 2024 reached -$90.9 million, down 121.99%, while the annual FY2024 figure was -$90.9 million, 121.99% down from the prior year.
  • Operating Income for Q4 2024 was -$45.0 million at Perspective Therapeutics, down from -$18.6 million in the prior quarter.
  • Across five years, Operating Income topped out at $299000.0 in Q4 2021 and bottomed at -$45.0 million in Q4 2024.
  • The 5-year median for Operating Income is -$3.8 million (2022), against an average of -$7.7 million.
  • The largest annual shift saw Operating Income surged 134.25% in 2021 before it crashed 1979.93% in 2022.
  • A 5-year view of Operating Income shows it stood at -$873000.0 in 2020, then soared by 134.25% to $299000.0 in 2021, then plummeted by 1979.93% to -$5.6 million in 2022, then tumbled by 107.72% to -$11.7 million in 2023, then crashed by 285.27% to -$45.0 million in 2024.
  • Per Business Quant, the three most recent readings for CATX's Operating Income are -$45.0 million (Q4 2024), -$18.6 million (Q3 2024), and -$14.3 million (Q2 2024).